Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

OBJECTIVE: To estimate the prevalence of elevated brain amyloid and reduced cortical thickness (as a marker for neurodegeneration) in a defined population.

METHODS: Mayo Clinic Study of Aging participants underwent MRI to assess a composite Alzheimer disease (AD) signature cortical thickness measure and PET to assess brain amyloid accumulation. Participants were characterized as having elevated amyloid (A+/A-), reduced cortical thickness (N+/N-), and A+N+, A+N-, A-N+, or A-N-. The prevalence of AD biomarkers was derived by adjusting for nonparticipation and standardizing to the Olmsted County, Minnesota, population.

RESULTS: Among 1,646 participants without dementia (mean age 70.8 years; 53.2% men), the prevalence (95% confidence interval) of amyloidosis was 21.1% (19.1%-23.2%): women, 24.3%; men, 17.5%. The prevalence of reduced cortical thickness was 28.9% (26.4%-31.5%): women, 27.9%; men, 30.2%. The prevalence estimates of biomarker categories were as follows: A-N-: 61.4%; A+N-: 9.7%; A-N+: 17.4%; and A+N+: 11.5%, and varied by sex and by APOE ε4 carrier status. In men, prevalence estimates were as follows: A-N-: 62.6%; A+N-: 7.3%; A-N+: 19.9%; and A+N+: 10.2%. In women, prevalence estimates were as follows: A-N-: 60.4%; A+N-: 11.7%; A-N+: 15.3%; and A+N+: 12.6%. In ε4 carriers, prevalence estimates were as follows: A-N-: 54.6%; A+N-: 16.6%; A-N+: 12.4%; and A+N+: 16.4%. In non-ε4 carriers, prevalence estimates were as follows: A-N-: 63.3%; A+N-: 6.9%; A-N+: 19.9%; and A+N+: 10.0%.

CONCLUSIONS: These prevalence estimates are important for understanding age-related trends in amyloid positivity and AD signature cortical thickness in the population, and for potentially projecting the future burden of biomarkers in elderly persons.

Original languageEnglish (US)
Pages (from-to)2039-2048
Number of pages10
JournalNeurology
Volume89
Issue number20
DOIs
StatePublished - Nov 14 2017

Fingerprint

Alzheimer Disease
Biomarkers
Amyloid
Population
Brain
Amyloidosis
Dementia
Confidence Intervals

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

@article{ed9a7434e8784c3f957a71ffb89520ed,
title = "Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers",
abstract = "OBJECTIVE: To estimate the prevalence of elevated brain amyloid and reduced cortical thickness (as a marker for neurodegeneration) in a defined population.METHODS: Mayo Clinic Study of Aging participants underwent MRI to assess a composite Alzheimer disease (AD) signature cortical thickness measure and PET to assess brain amyloid accumulation. Participants were characterized as having elevated amyloid (A+/A-), reduced cortical thickness (N+/N-), and A+N+, A+N-, A-N+, or A-N-. The prevalence of AD biomarkers was derived by adjusting for nonparticipation and standardizing to the Olmsted County, Minnesota, population.RESULTS: Among 1,646 participants without dementia (mean age 70.8 years; 53.2{\%} men), the prevalence (95{\%} confidence interval) of amyloidosis was 21.1{\%} (19.1{\%}-23.2{\%}): women, 24.3{\%}; men, 17.5{\%}. The prevalence of reduced cortical thickness was 28.9{\%} (26.4{\%}-31.5{\%}): women, 27.9{\%}; men, 30.2{\%}. The prevalence estimates of biomarker categories were as follows: A-N-: 61.4{\%}; A+N-: 9.7{\%}; A-N+: 17.4{\%}; and A+N+: 11.5{\%}, and varied by sex and by APOE ε4 carrier status. In men, prevalence estimates were as follows: A-N-: 62.6{\%}; A+N-: 7.3{\%}; A-N+: 19.9{\%}; and A+N+: 10.2{\%}. In women, prevalence estimates were as follows: A-N-: 60.4{\%}; A+N-: 11.7{\%}; A-N+: 15.3{\%}; and A+N+: 12.6{\%}. In ε4 carriers, prevalence estimates were as follows: A-N-: 54.6{\%}; A+N-: 16.6{\%}; A-N+: 12.4{\%}; and A+N+: 16.4{\%}. In non-ε4 carriers, prevalence estimates were as follows: A-N-: 63.3{\%}; A+N-: 6.9{\%}; A-N+: 19.9{\%}; and A+N+: 10.0{\%}.CONCLUSIONS: These prevalence estimates are important for understanding age-related trends in amyloid positivity and AD signature cortical thickness in the population, and for potentially projecting the future burden of biomarkers in elderly persons.",
author = "Roberts, {Rosebud O} and Knopman, {David S} and Syrjanen, {Jeremy A.} and Aakre, {Jeremiah A.} and Maria Vassilaki and Kremers, {Walter K} and Mielke, {Michelle M} and Machulda, {Mary Margaret} and Jonathan Graff-Radford and Geda, {Yonas Endale} and Vemuri, {Prashanthi D} and Val Lowe and Jack, {Clifford R Jr.} and Petersen, {Ronald Carl}",
year = "2017",
month = "11",
day = "14",
doi = "10.1212/WNL.0000000000004652",
language = "English (US)",
volume = "89",
pages = "2039--2048",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "20",

}

TY - JOUR

T1 - Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers

AU - Roberts, Rosebud O

AU - Knopman, David S

AU - Syrjanen, Jeremy A.

AU - Aakre, Jeremiah A.

AU - Vassilaki, Maria

AU - Kremers, Walter K

AU - Mielke, Michelle M

AU - Machulda, Mary Margaret

AU - Graff-Radford, Jonathan

AU - Geda, Yonas Endale

AU - Vemuri, Prashanthi D

AU - Lowe, Val

AU - Jack, Clifford R Jr.

AU - Petersen, Ronald Carl

PY - 2017/11/14

Y1 - 2017/11/14

N2 - OBJECTIVE: To estimate the prevalence of elevated brain amyloid and reduced cortical thickness (as a marker for neurodegeneration) in a defined population.METHODS: Mayo Clinic Study of Aging participants underwent MRI to assess a composite Alzheimer disease (AD) signature cortical thickness measure and PET to assess brain amyloid accumulation. Participants were characterized as having elevated amyloid (A+/A-), reduced cortical thickness (N+/N-), and A+N+, A+N-, A-N+, or A-N-. The prevalence of AD biomarkers was derived by adjusting for nonparticipation and standardizing to the Olmsted County, Minnesota, population.RESULTS: Among 1,646 participants without dementia (mean age 70.8 years; 53.2% men), the prevalence (95% confidence interval) of amyloidosis was 21.1% (19.1%-23.2%): women, 24.3%; men, 17.5%. The prevalence of reduced cortical thickness was 28.9% (26.4%-31.5%): women, 27.9%; men, 30.2%. The prevalence estimates of biomarker categories were as follows: A-N-: 61.4%; A+N-: 9.7%; A-N+: 17.4%; and A+N+: 11.5%, and varied by sex and by APOE ε4 carrier status. In men, prevalence estimates were as follows: A-N-: 62.6%; A+N-: 7.3%; A-N+: 19.9%; and A+N+: 10.2%. In women, prevalence estimates were as follows: A-N-: 60.4%; A+N-: 11.7%; A-N+: 15.3%; and A+N+: 12.6%. In ε4 carriers, prevalence estimates were as follows: A-N-: 54.6%; A+N-: 16.6%; A-N+: 12.4%; and A+N+: 16.4%. In non-ε4 carriers, prevalence estimates were as follows: A-N-: 63.3%; A+N-: 6.9%; A-N+: 19.9%; and A+N+: 10.0%.CONCLUSIONS: These prevalence estimates are important for understanding age-related trends in amyloid positivity and AD signature cortical thickness in the population, and for potentially projecting the future burden of biomarkers in elderly persons.

AB - OBJECTIVE: To estimate the prevalence of elevated brain amyloid and reduced cortical thickness (as a marker for neurodegeneration) in a defined population.METHODS: Mayo Clinic Study of Aging participants underwent MRI to assess a composite Alzheimer disease (AD) signature cortical thickness measure and PET to assess brain amyloid accumulation. Participants were characterized as having elevated amyloid (A+/A-), reduced cortical thickness (N+/N-), and A+N+, A+N-, A-N+, or A-N-. The prevalence of AD biomarkers was derived by adjusting for nonparticipation and standardizing to the Olmsted County, Minnesota, population.RESULTS: Among 1,646 participants without dementia (mean age 70.8 years; 53.2% men), the prevalence (95% confidence interval) of amyloidosis was 21.1% (19.1%-23.2%): women, 24.3%; men, 17.5%. The prevalence of reduced cortical thickness was 28.9% (26.4%-31.5%): women, 27.9%; men, 30.2%. The prevalence estimates of biomarker categories were as follows: A-N-: 61.4%; A+N-: 9.7%; A-N+: 17.4%; and A+N+: 11.5%, and varied by sex and by APOE ε4 carrier status. In men, prevalence estimates were as follows: A-N-: 62.6%; A+N-: 7.3%; A-N+: 19.9%; and A+N+: 10.2%. In women, prevalence estimates were as follows: A-N-: 60.4%; A+N-: 11.7%; A-N+: 15.3%; and A+N+: 12.6%. In ε4 carriers, prevalence estimates were as follows: A-N-: 54.6%; A+N-: 16.6%; A-N+: 12.4%; and A+N+: 16.4%. In non-ε4 carriers, prevalence estimates were as follows: A-N-: 63.3%; A+N-: 6.9%; A-N+: 19.9%; and A+N+: 10.0%.CONCLUSIONS: These prevalence estimates are important for understanding age-related trends in amyloid positivity and AD signature cortical thickness in the population, and for potentially projecting the future burden of biomarkers in elderly persons.

UR - http://www.scopus.com/inward/record.url?scp=85037714814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037714814&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000004652

DO - 10.1212/WNL.0000000000004652

M3 - Article

VL - 89

SP - 2039

EP - 2048

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 20

ER -